Low folate and the risk of cognitive and functional deficits in the very old: the Monzino 80-plus study.

 
J Am Coll Nutr. 2006 Dec;25(6):502-8. Related Articles, Links
Click here to read 
Low folate and the risk of cognitive and functional deficits in the very old: the Monzino 80-plus study.

Tettamanti M, Garri MT, Nobili A, Riva E, Lucca U.

Laboratory of Geriatric Neuropsychiatry, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milano, Italy.

OBJECTIVE: To cross sectionally investigate the association of serum vitamin B(12) and folate concentrations with cognitive and functional ability in the very old in the general population. METHODS: Serum vitamin B(12) and folate concentrations were assessed in 471 consenting subjects participating in the Monzino 80-plus study (mean age: 87.4 years), a door-to-door population-based survey among very old subjects living in Northern Italy. Cognitive and functional evaluations included Mini-Mental State Examination (MMSE), Instrumental Activities of Daily Living (IADL) and Spontaneous Behavior Interview-basic Activities of Daily Living (SBI-bADL). RESULTS: MMSE, IADL and SBI-bADL scores were all significantly correlated with folate concentrations (respectively: r = 0.36, r = -0.39, r = -0.35; p < 0.0001), while no significant associations were found with vitamin B(12) concentrations. When entered into multiple linear regression analyses with several covariates, folate showed a highly significant, curvilinear association with both cognitive and functional scores (p < 0.0001). Subjects in low and middle folate tertiles had significantly higher odds ratios for dementia (p < 0.0001; adjusted ORs = 5.40 and 6.56, lower 95% CIs 2.53 and 3.11, higher 95% CIs 12.73 and 15.29). CONCLUSIONS: Findings of this population-based study suggest that subclinical folate deficiency may represent a risk factor for the cognitive decline associated with aging that could contribute to AD as well as other dementia development.

Publication Types:

PMID: 17229897 [PubMed – indexed for MEDLINE]

Posted in Aging |

Back pain without radiculitis as an initial manifestation of Lyme disease: two cases

 
Presse Med. 2007 Jan;36(1 Pt 1):61-3. Epub 2006 Dec 11. Related Articles, Links
Click here to read 
[Back pain without radiculitis as an initial manifestation of Lyme disease: two cases]

[Article in French]

Chanier S, Lauxerois M, Rieu V.

Service de Medecine, Centre Hospitalier, Thiers. sevchanier@voila.fr

INTRODUCTION: The most frequent neurological expression of Lyme disease (borreliosis) during its secondary phase is meningoradiculitis, but atypical presentations occur. Lyme disease must be considered especially in endemic areas and during the summer (May-October). CASES: We report cases of two patients with unusual clinical presentations of neuroborreliosis. Both had acute inflammatory back pain, resistant to the usual analgesic treatment. Both patients responded negatively to questions about tick bites and erythema migrans. Laboratory tests revealed an inflammatory process in only one patient. Lyme disease was confirmed by lymphocytic meningitis and serological tests positive for Borrelia in blood (both cases) and cerebrospinal fluid (one case). Antibiotic treatment led to the disappearance of pain and the normalization of laboratory tests. DISCUSSION: Inflammatory back pain, even without radiculitis, may be related to Lyme disease in endemic areas.

Publication Types:

PMID: 17261450 [PubMed – indexed for MEDLINE]

Posted in News | Tagged |

It pays to be nice: employer-worker relationships and the management of back pain claims.

 
J Occup Environ Med. 2007 Feb;49(2):214-25. Related Articles, Links
Click here to read 
It pays to be nice: employer-worker relationships and the management of back pain claims.

Butler RJ, Johnson WG, Cote P.

Department of Economics, Brigham Young University, Provo, UT 84602, USA. richard_butler@byu.edu

OBJECTIVE: To quantify the influence that workers’ satisfaction with the firm’s treatment of their disability claim and their health care provider has on workers’ return to work (RTW) following onset of occupational LBP. METHODS: Using a prospective survey on back pain, medical treatment, and workers’ satisfaction, we employ nonparametric and logistic analyses to see how satisfaction affects RTW. RESULTS: Workers’ satisfaction with their employer’s treatment of their disability claim is more important in explaining RTW than satisfaction with health care providers or expectations about recovery. Dissatisfied workers have worse return to work outcomes because they are more likely to have time lost claims and are more likely to have multiple spells of joblessness. CONCLUSIONS: Workers’ RTW is more responsive to their satisfaction with how the firm treated their disability claim than with their satisfaction with the health care provider. Satisfaction of both types plays an important role in determining RTW.

PMID: 17293761 [PubMed – indexed for MEDLINE]

Posted in News | Tagged |

Levodopa modifies pain thresholds in Parkinson’s disease patients

 
Rev Neurol (Paris). 2007 Jan;163(1):66-71. Related Articles, Links
Click here to read 
[Levodopa modifies pain thresholds in Parkinson’s disease patients]

[Article in French]

Slaoui T, Mas-Gerdelat A, Ory-Magne F, Rascol O, Brefel-Courbon C.

Service de Neurologie, CHU, Toulouse. tarikslaoui@yahoo.com

OBJECTIVE: To assess levodopa dose effect on pain thresholds in Parkinson’s disease (PD) patients using an experimental nociceptive thermal stimulation. PATIENTS AND METHODS: We evaluated pain thresholds in 20 PD patients treated by dopaminergic drugs. We assessed heat and cold pain thresholds by using 2 different methods (method of limits and method of levels), intensity-response curve and tolerance threshold. Each PD patient was evaluated in two conditions: ON (after administration of leovdopa and OFF (after acute levodopa withdrawal). The order was randomized. RESULTS: The mean age of patients was 652+/-9.9 years and the mean duration was 9.3+/-3.3 years. Heat pain thresholds were statistically higher in ON versus OFF condition using both methods (44.1+/-3,6 degrees C versus 42.3+/-3,1 degrees C, method of levels, p=0.02). Cold pain thresholds were statistically higher in ON versus OFF condition only using method of levels (17.9+/-4,4 degrees C versus 19.6+/-4,2 degrees C, p=0.02). Heat pain tolerance was statistically higher in ON versus OFF condition (21.4+/-21.6 seconds versus 14.7+/-20.3 seconds, p=0.02). CONCLUSION: This study showed that levodopa increased heat and cold pain thresholds and heat pain tolrance in PD patients. This suggests that dopaminergic drugs could have an analgesic effects on PD related pain.

Publication Types:

PMID: 17304174 [PubMed – in process]

Posted in News | Tagged |

Low-dose naltrexone therapy improves active Crohn’s disease.

 
Am J Gastroenterol. 2007 Apr;102(4):820-8. Epub 2007 Jan 11. Related Articles, Links
Click here to read 
Low-dose naltrexone therapy improves active Crohn’s disease.

Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS.

Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.

OBJECTIVES: Endogenous opioids and opioid antagonists have been shown to play a role in healing and repair of tissues. In an open-labeled pilot prospective trial, the safety and efficacy of low-dose naltrexone (LDN), an opioid antagonist, were tested in patients with active Crohn’s disease. METHODS: Eligible subjects with histologically and endoscopically confirmed active Crohn’s disease activity index (CDAI) score of 220-450 were enrolled in a study using 4.5 mg naltrexone/day. Infliximab was not allowed for a minimum of 8 wk prior to study initiation. Other therapy for Crohn’s disease that was at a stable dose for 4 wk prior to enrollment was continued at the same doses. Patients completed the inflammatory bowel disease questionnaire (IBDQ) and the short-form (SF-36) quality of life surveys and CDAI scores were assessed pretreatment, every 4 wk on therapy and 4 wk after completion of the study drug. Drug was administered by mouth each evening for a 12-wk period. RESULTS: Seventeen patients with a mean CDAI score of 356 +/- 27 were enrolled. CDAI scores decreased significantly (P= 0.01) with LDN, and remained lower than baseline 4 wk after completing therapy. Eighty-nine percent of patients exhibited a response to therapy and 67% achieved a remission (P < 0.001). Improvement was recorded in both quality of life surveys with LDN compared with baseline. No laboratory abnormalities were noted. The most common side effect was sleep disturbances, occurring in seven patients. CONCLUSIONS: LDN therapy appears effective and safe in subjects with active Crohn’s disease. Further studies are needed to explore the use of this compound.

Publication Types:

PMID: 17222320 [PubMed – in process]

Posted in Psychiatry/Neurology |